CBDUAL BIOTECHNOLOGY CORP LAUNCHES REVOLUTIONARY TEETH POLISHING PASTE with Cannabidiol (CBD)
Thousand Oaks, CA –November 8, 2019/ CBDual Biotechnology Corp.(“the Company”), a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) a developer of CBD based oral healthcare products, is excited to announce today the launch of a revolutionary Teeth Polishing Paste containing Cannabidiol (CBD). This is the first and only CBD dental polishing system of its kind that promotes both enamel and gum health through a customized dental care program.
Branded as “CB-Dual Prophy™”, the new product includes a stain removing ingredients and polishing paste as well as a unique CBD oil formulation, customized to each specific patient’s needs. This new compounded formulation, with dual benefit, allows dentists and hygienists to offer a potentially healthier and gentler approach to teeth polishing to preserve enamel and improve gums health.
“CB-Dual Prophy™ is a revolutionary new product that will change the whole dental industry’s approach to teeth polishing,” said Dr. Greg Rubin, CEO and Founder of the Company. “Teeth polishing in the dental industry has been known as having no therapeutic value, but by incorporating our CBD oil, we are looking to potentially improve overall gum health. Published clinical research indicates that CBD oil demonstrates both antibacterial and anti-inflammatory properties on gums.”
To maintain optimal oral health, the American Dental Association (ADA) recommends regular dental visits, at intervals determined by a dentist. In light of a study published in the Journal of Dental Research titled “Patient Stratification for Preventive Care in Dentistry,” the ADA wants to remind consumers that the frequency of their regular dental visits should be tailored by their dentists to accommodate for their current oral health status and health history.
Our team of dentists, scientists and product developers have done extensive research and testing to create the best and unique formula. CBDUAL Biotechnology has partnered with 1000SMILES DENTAL to engage in product testing on volunteers.
CB-Dual Prophy™ Teeth Polishing Paste will be manufactured gluten-free, sweetened with xylitol with a variety of flavors. In addition, fluoride can be added on demand for patients who need an extra layer of protection.
About CBDual Biotechnology Corp.
THC Farmaceuticals, Inc.: (OTC: CBDG) through its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The company’s facility is located in Southern California where we provide easy access for patients to participate in clinical trials of new medical cannabis medications and psilocybin therapies, and products. CBDual Biotechnology Corp is a privately held, US Based Biotechnology company with propriety technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes overall oral health due to higher effectiveness of the delivery methodology. The company was founded in 2016 and is headquartered in California, with its R&D in the US and Israel.
For additional information visit the company’s website: https://cbdual.com and https://cbdg.com/
Follow us on Twitter @THCFarma and @CBDualBiotech
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by our parent company in its reports filed with the Securities and Exchange Commission and the OTCMarkets, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.